Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

NCT ID: NCT03870919

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-10-23
• Study Completion Date: 2027-10-23

Brief Summary

Approximately 3.5% to 6% of newly diagnosed breast cancer patients are stage IV metastatic. De novo metastatic breast cancer accounts for 20% to 25% of these cases. Despite a decrease in mortality in Europe and North America due to early detection and access to treatment, breast cancer remains the 2ⁿᵈ leading cause of cancer deaths in developed countries after lung cancer and the world's leading cause.

In the ESME French national retrospective cohort (NCT03275311), the newly diagnosed estrogen receptor (ER)-positive and HER2-negative (luminal) metastatic patients had a 59.1 months overall survival (OS) for pre-menopausal women and 44.7 months for postmenopausal women. In the same cohort, the median OS was 47.4 months for de novo metastatic patients with hormone receptor (HR)-positive / HER2-negative breast cancer.

The most important current treatment for metastatic breast cancer remains systemic therapy. Surgery and radiation are mainly used to treat symptoms. However, more than 15 retrospective studies have assessed the impact of locoregional treatment on relapse and OS. These studies suggested an improvement of the OS in patients with de novo metastatic breast cancer thanks to the addition of locoregional treatment to systemic therapy. Recent data from the ESME cohort suggest that patients with de novo luminal or HER2-positive metastatic breast cancer may benefit from local treatment of the primary tumor.

Several prospective trials have attempted to demonstrate the benefit of locoregional treatment with mixed results. This can be explained by a limited power of statistical analysis, on the recruitment of patients with breast cancer of all types, and on a limited access to effective systemic therapies in some cases and all before the area of anti CD4/6 which is the current standard treatment in patients with HR-positive / HER2-negative luminal metastatic disease.

However, guidelines indicate that a "multimodal approach, including curative locoregional treatments, should be considered". As a result, many clinicians offer locoregional treatment of the primary tumor, especially if there is a good response to the first line of systematic treatment.

Taken together, these data underscore the need for an evaluation of the value of combined therapy - endocrine therapy - CDK4/6 inhibitor and locoregional treatment - in this population of patients with newly diagnosed HR-positive / HER2-negative breast cancer.

Conditions

Breast Cancer Stage IV; Radiotherapy; Surgery

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Palbociclib + locoregional treatment

All patients will receive the standard of care treatment ie Palbociclib + letrozole for 24-26 weeks (a delay of +/- 2 weeks to initiate the locoregional treatment is authorized after the day 1 of cycle 1 of palbociclib plus letrozole). After this period, patient will have the most adapted locoregional treatment ie surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy. The palbociclib will be continued until progression

Group Type: OTHER

Palbociclib

Intervention Type: DRUG

The included patients will first receive the following systemic treatment according standard of care:

• Non-steroidal aromatase inhibitor (letrozole)
• Palbociclib
• Monthly Luteinizing hormone-releasing hormone (LHRH) analogue for non-menopausal patients only. Surgical bilateral oophorectomy is an acceptable option.

locoregional treatment

Intervention Type: OTHER

After normally 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy

Interventions

Palbociclib

The included patients will first receive the following systemic treatment according standard of care:

• Non-steroidal aromatase inhibitor (letrozole)
• Palbociclib
• Monthly Luteinizing hormone-releasing hormone (LHRH) analogue for non-menopausal patients only. Surgical bilateral oophorectomy is an acceptable option.

Intervention Type: DRUG

locoregional treatment

After normally 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Women with newly diagnosed and histologically proven de novo adenocarcinoma of the breast, Any T, any N, with at least one metastatic site measurable and/or non-measurable according to Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 and/or PET Response Criteria in Solid Tumours (PERCIST) v1.0 and/or MD Anderson bone response criteria (MDA criteria). For patients with only bone metastases, at least one lytic and non-irradiated lesion must be present NB: Bilateral breast cancer is allowed only if tumours present similar histological criteria (morphological subtype, ER and HER2 status).

2. Estrogen Receptor (ER)-positive and HER2-negative breast cancer. To be considered as ER-positive, the biopsy of the primary tumour must display at least 10% of cancer cells with positive ER staining. HER2-positive is defined as IHC3+ or FISH/CISH amplified according to 2018 criteria

3. Age ≥18 years

4. Eastern Cooperative Oncology Group (ECOG) ≤2

5. Indication for treatment with palbociclib and letrozole (with or without ovarian suppression)

6. Diagnostic FFPE tumour sample and/or frozen primary breast tumour sample available

7. Women of childbearing potential must have a negative serum or urine pregnancy test done within 14 days before inclusion

8. Patients must agree to use adequate contraception methods for the duration of the study and for within 21 days after completing treatment

9. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and any protocol-related procedures including absence of co-morbidities preventing surgery and or radiotherapy and any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. Those conditions should be discussed with the patient before registration in the trial

10. Patient affiliated to a social security system

11. Written informed consent obtained prior to performing any protocol-related procedures including screening evaluations

Exclusion Criteria

1. Patients with advanced, symptomatic, visceral spread at a risk for short-term, life-threatening complications according to investigator judgement and at risk for visceral crisis as defined by ABC4*

2. Women with previously diagnosed and treated ipsilateral adenocarcinoma of the breast

3. Women with previously treated or concomitant contralateral breast cancer except for Ductal carcinoma in situ (DCIS) treated with curative intent

4. Patients with another concomitant cancer

5. Concurrent enrolment in another clinical trial in which investigational therapies are administered or administration of an investigational drug within 30 days before inclusion

6. Pregnant women or women who are breast-feeding

7. Inability or willingness to swallow oral medication

8. HIV, hepatitis (B and C)

9. Active infection

10. Prior therapy for metastatic breast cancer (systemic or local)

11. Persons deprived of their freedom or under guardianship or incapable of giving consent

• Visceral crisis is defined as severe organ dysfunction as assessed by signs and symptoms, laboratory studies and rapid progression of disease. Visceral crisis is not the mere presence of visceral metastases but implies important visceral compromise leading to a clinical indication for a more rapidly efficacious therapy, particularly since another treatment option at progression will probably not be possible.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Pfizer

INDUSTRY

Sponsor Role: collaborator

UNICANCER

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Claire Bonneau, MD

Role: PRINCIPAL_INVESTIGATOR

Institut Curie

Locations

Institut de Cancérologie de l'Ouest-Site Paul Papin

Angers, , France

Institut Sainte Catherine

Avignon, , France

Centre François Baclesse

Caen, , France

Hôpital privé sainte Marie

Chalon-sur-Saône, , France

CH Cholet

Cholet, , France

Centre Jean Perrin

Clermont-Ferrand, , France

Centre George François Leclerc

Dijon, , France

Centre Léon Bérard

Lyon, , France

Hôpital St Joseph

Marseille, , France

Institut Paoli Calmettes

Marseille, , France

Hôpital saint Eloi CHU Montpellier

Montpellier, , France

ICM Val d'Aurelle

Montpellier, , France

Institut Curie Site Paris

Paris, , France

Hôpital Saint Louis APHP

Paris, , France

Hôpital St Joseph

Paris, , France

Hôpital Tenon

Paris, , France

Centre Hospitalier de Pau

Pau, , France

CH René Dubos

Pontoise, , France

Institut Jean Godinot

Reims, , France

Centre Eugène Marquis

Rennes, , France

Institut Curie Hôpital René Huguenin

Saint-Cloud, , France

Hôpital Privé à Saint Grégoire

Saint-Grégoire, , France

GCS RISSA - Institut de cancérologie Paris Nord

Sarcelles, , France

Institut Claudius Regaud

Toulouse, , France

Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, , France

Gustave Roussy

Villejuif, , France

Countries

France

Other Identifiers

2019-A00570-57

Identifier Type: REGISTRY

Identifier Source: secondary_id

UC-0140/1814

Identifier Type: -

Identifier Source: org_study_id